elacestrant
elacestrant: developed by 1 company · 15 clinical trials tracked.
elacestrant evidence translation
What we can confirm
15 tracked trials
What it means
What to watch
Prepared research question
How could elacestrant → RDUS affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 5 study sponsors
Related indications
Development Pipeline (1)
| Company | Phase |
|---|---|
| Radius Health, Inc. (RDUS) ER+/HER2- advanced or metastatic breast cancer | Phase 3 |
Clinical Trials (15)showing 10 most recent
A Phase II Study of Elacestrant, an Oral Selective Estrogen Receptor Degrader (SERD) Combined With Everolimus in Patients With Recurrent or Metastatic ER-Positive (ER+) Endometrial Cancer (ELAVERA)
Primary endpoint: Proportion of patients progression-free
A Phase 2 Study Evaluating the Efficacy of Elacestrant in Patients With Estrogen Receptor Positive Uterine Sarcomas
Primary endpoint: Objective Response Rate (ORR)
A Phase II Multi-Center Open-label Randomized Study of CAPecitabine in Combination With ELAcestrant Versus Capecitabine Alone in Advanced Estrogen Receptor-Positive Breast Cancer (CAPELA)
Primary endpoint: Progression Free Survival (PFS) in ESR1 mutant population
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Primary endpoint: Recommended phase II dose (RP2D)
A Single Arm Phase II Trial of Circulating Tumor DNA-guided Adjuvant Therapy With Elacestrant in Adults With Hormone Receptor Positive HER2 Negative Breast Cancers at Risk for Late Recurrence (CATE)
Primary endpoint: Assessing Elacestrant's Impact on ctDNA Clearance in ER+HER2- Breast Cancer Patients
A Randomized Phase 3, Double-Blind, Placebo-Controlled Study of Elacestrant Plus Everolimus Versus Elacestrant in Patients With ER+/HER2-, ESR1mut Advanced Breast Cancer Progressing to Endocrine Therapy and CDK4/6 Inhibitors
Primary endpoint: To demonstrate superiority of elacestrant+everolimus vs. elacestrant+placebo in prolonging PFS based on a BIRC in patients with ER[+]/HER2[-], ESR1-mutated, ABC that have previously received ET+CDK4/6i (all patients).
Immunologic Targeting of Native and Mutated ESR1 Receptor for Treatment of Hormone Receptor Expressing Metastatic Breast Cancer
Primary endpoint: Rate of Successful Completion
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
Elacestrant Versus Standard Endocrine Therapy in Women and Men With Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer With High Risk of Recurrence-A Global, Multicenter, Randomized, Open-label Phase 3 Study
Primary endpoint: Invasive Breast Cancer-Free Survival (IBCFS)
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Primary endpoint: Distant metastasis free survival (DMFS)
Frequently asked questions
Who is developing elacestrant?
elacestrant is being developed by Radius Health, Inc..
How many clinical trials involve elacestrant?
BioSniper tracks 15 clinical trials involving elacestrant.